TABLE 4.
Comparison of clinical characteristics of patients who underwent genome biopsy TBB and CT‐guided biopsy
| Final TBB patients | Final CT‐guided patients | p | |
|---|---|---|---|
| (n = 99) | (n = 17) | ||
| Age‐median, (range) | |||
| Median | 67 (32–90) | 69 (36–82) | 0.401 |
| Sex, n (%) | |||
| Male | 58 (58.6) | 8 (47.1) | 0.432 |
| Female | 41 (41.4) | 9 (52.9) | |
| Histology, n (%) | |||
| Ad including | 0.094 | ||
| Ad + SCLC | 75 (75.8) | 8 (47.1) | |
| Ad + Sq | |||
| Sq | 16 (16.1) | 7 (41.2) | |
| NSCLC | 8 (8.1) | 2 (11.7) | |
| Stage‐n. (%) | |||
| IIIA,B | 20 (20.2) | 5 (29.4) | 0.394 |
| IVA | 32 (32.3) | 2 (11.7) | |
| IVB | 47 (47.5) | 10 (58.9) | |
| Tumor location 1, n (%) | |||
| Central | 34 (34.3) | 0 (0) | <0.05 |
| Peripheral | 65 (65.7) | 17 (100) | |
| Tumor location 2, n (%) | |||
| Right | 0.7 | ||
| Upper and Middle | 29 (29.3) | 4 (23.5) | |
| Lower | 24 (24.2) | 4 (23.5) | |
| Left | |||
| Upper | 24 (24.2) | 3 (17.7) | |
| Lower | 22 (22.3) | 6 (35.3) | |
| Maximum diameter of tumor(mm) | |||
| Median (range) | 40.3 (14.7–102.3) | 49.8 (24.6–85.6) | 0.076 |
| Tumor nuclei content (%) | |||
| Median (range) | 50 (10–90) | 70 (20–80) | <0.05 |
| Necrosis tissue content (%) | |||
| Median (range) | 10 (0–90) | 5 (0–90) | 0.086 |
| Tissue area (mm2) | |||
| Median (range) | 1.7 (0.2–3.6) | 5.6 (0.6–11.5) | <0.001 |
| DNA(μg/μl) | |||
| Median (range) | 0.08 (0.01–0.33) | 0.08 (0.01–0.17) | 0.382 |
| RNA(μg/μl) | |||
| Median (range) | 0.02 (0.01–0.28) | 0.01 (0.01–0.11) | 0.11 |
| DNA/Tissue are (μg/μl/mm2 × 10−2) | |||
| Median (range) | 1.53 (0.12–16.7) | 0.68 (0.25–1.10) | <0.001 |
| RNA/Tissue are (μg/μl/mm2 × 10−2) | |||
| Median (range) | 0.42 (0.09–14.8) | 0.14 (0.05–2.65) | <0.001 |
| NGS success rate | 82/99 (82.8) | 12/17 (70.6) | 0.312 |
| DNA‐based NGS | 88/99 (88.9) | 16/17 (94.1) | 1.000 |
| RNA‐based NGS | 90/99 (90.9) | 13/17 (76.5) | 0.098 |